FDA Issues Final Guidance on Prescription Drug Apps and Software

The U.S. Food and Drug Administration (FDA) issued final guidance on October 20, 2026, outlining how pharmaceutical companies should develop, distribute, and label software applications used alongside prescription medicines. The guidance clarifies when application content may be subject to FDA submission requirements, when an application should be referenced in a medicine’s official labeling, and what companies should submit to the agency.

The FDA aims to help ensure that information delivered through these applications is accurate, evidence-based, and clearly communicated to patients and healthcare professionals, while maintaining the safety and effectiveness standards expected of prescription medicines.

Key Regulatory Questions

The final guidance addresses three main questions for pharmaceutical companies:

• When application content is considered FDA-required labeling rather than promotional labeling.
• When an application should be referenced in a medicine’s official prescribing information.
• What information companies should submit to the FDA when distributing application content to users.

These considerations are particularly relevant as digital tools become more integrated into medication management and patient care. Monitoring regulatory developments and assessing their potential implications across markets are important parts of regulatory planning. Baupharma supports this work through its Regulatory Intelligence & Foresight services.

Two Categories of Companion Software

The FDA identifies two categories of software used alongside prescription medicines: applications connected to medical devices and standalone applications. The guidance outlines different considerations for their inclusion in official prescribing information.

1. Applications Connected to Medical Devices

Applications connected to a medical device, such as an app paired with an asthma inhaler, generally should be described in the medicine’s official prescribing label. The FDA highlights the central role these applications can play in how the medicine is used.

2. Standalone Applications

Standalone applications include symptom trackers, dose reminders, and health coaching tools. According to the FDA, these applications should be included in prescribing information when a company can demonstrate that the application is essential for the safe and effective use of the medicine or provides a meaningful clinical benefit.

The announcement also states that, in most cases, content displayed to users through companion applications will be treated as promotional material, consistent with the FDA’s approach to other forms of drug advertising.

For further context on prescription drug labeling, the FDA provides resources explaining the components of human prescription drug labeling and their role in communicating essential information for safe and effective medicine use.

Digital Health Oversight and Regulatory Alignment

The FDA describes the guidance as part of its ongoing effort to modernize regulatory oversight in response to rapidly evolving digital health technologies. The agency identifies digital health as a priority area with potential to improve patient care and emphasizes the importance of responsible, risk-proportionate oversight.

The announcement also highlights alignment between the FDA’s drug and device centers. According to the agency, this coordinated approach is intended to provide developers with a clearer and more consistent pathway for bringing safe and effective digital health technologies to patients.

Further information on the agency’s broader work in this area is available through its Digital Health Technologies focus area.

Supporting Reliable Information as Companion Apps Evolve

The FDA notes that companion applications are moving beyond basic functions, such as dose reminders, toward tools that can adapt to individual patients. The agency states that finalizing the guidance provides pharmaceutical companies and their technology partners with a more stable foundation as these technologies advance.

The FDA also emphasizes the importance of ensuring that patients and healthcare professionals can trust the information delivered through these applications. Its broader objective is to reduce unnecessary uncertainty for developers and manufacturers while preserving the safety and effectiveness standards on which patients and healthcare professionals rely.

As digital health tools evolve, the regulatory assessment of product information remains important. For related context on maintaining consistency between global safety information and regional product documentation, see Baupharma’s article on CCDS-to-SmPC adaptation and EU product information compliance.

Conclusion

The FDA’s final guidance provides recommendations on the regulatory treatment of software used alongside prescription medicines. It addresses the distinction between FDA-required and promotional labeling, the circumstances in which companion applications should be referenced in official prescribing information, and submission-related considerations for companies distributing application content.

By distinguishing between software connected to medical devices and standalone applications, the FDA aims to clarify expectations for industry while supporting the responsible development of digital health technologies.

The full announcement and access to the final guidance are available on the FDA’s official website.